CRIS Current Research Information System

FINELLI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.101
EU - Europa 2.360
AS - Asia 2.056
AF - Africa 306
SA - Sud America 102
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 3
Totale 7.943
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.067
SG - Singapore 689
GB - Regno Unito 640
CN - Cina 553
IT - Italia 409
VN - Vietnam 398
SE - Svezia 355
DE - Germania 309
HK - Hong Kong 161
RU - Federazione Russa 131
IN - India 112
TG - Togo 92
FR - Francia 91
IE - Irlanda 81
JP - Giappone 78
BR - Brasile 76
SC - Seychelles 73
NL - Olanda 59
ZA - Sudafrica 58
EE - Estonia 52
NG - Nigeria 41
UA - Ucraina 37
CI - Costa d'Avorio 35
HR - Croazia 35
FI - Finlandia 34
BG - Bulgaria 27
BE - Belgio 25
CA - Canada 24
JO - Giordania 23
AT - Austria 22
CH - Svizzera 20
EU - Europa 15
AR - Argentina 13
PL - Polonia 9
MX - Messico 7
UZ - Uzbekistan 7
ID - Indonesia 6
BD - Bangladesh 5
IR - Iran 5
LB - Libano 5
EC - Ecuador 4
ES - Italia 4
GR - Grecia 4
TR - Turchia 4
CO - Colombia 3
IL - Israele 3
LT - Lituania 3
RO - Romania 3
AU - Australia 2
CZ - Repubblica Ceca 2
MA - Marocco 2
MY - Malesia 2
PY - Paraguay 2
TN - Tunisia 2
VE - Venezuela 2
AL - Albania 1
AZ - Azerbaigian 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GI - Gibilterra 1
GP - Guadalupe 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
RW - Ruanda 1
Totale 7.943
Salva come PNG Salva come JPEG
Città #
Southend 590
Singapore 456
Ashburn 349
Fairfield 306
Chandler 300
Santa Clara 216
Houston 191
Hong Kong 161
Ann Arbor 156
Bologna 146
Wilmington 142
Seattle 137
Woodbridge 130
Princeton 115
Beijing 101
Cambridge 101
Lomé 92
Dong Ket 82
Dublin 79
Boardman 78
Padova 59
Westminster 55
Nanjing 54
Tokyo 47
Abeokuta 41
Ho Chi Minh City 37
Shenyang 36
Abidjan 35
Jinan 35
Milan 34
Redwood City 34
Saint Petersburg 34
Hanoi 32
Medford 32
Changsha 30
New York 30
Berlin 27
Sofia 27
Helsinki 26
Los Angeles 26
Brussels 25
Nanchang 24
Amman 23
Hebei 23
Buffalo 22
Redondo Beach 22
Turin 22
Frankfurt am Main 17
Vienna 16
Bern 15
Dallas 15
San Diego 15
Jiaxing 14
Munich 14
Shanghai 14
Falls Church 13
Guangzhou 13
Menlo Park 12
Hangzhou 11
Norwalk 11
Tianjin 11
Bremen 10
Rome 10
Tappahannock 10
Yubileyny 10
Amsterdam 9
Dearborn 9
São Paulo 9
Zhengzhou 9
Florence 8
Haikou 8
Jacksonville 8
Montreal 8
Toronto 8
Turku 8
Valsamoggia 8
London 7
Orem 7
Warsaw 7
Biên Hòa 6
Bühl 6
Lanzhou 6
Mountain View 6
Taizhou 6
Andover 5
Chicago 5
Hefei 5
Hải Dương 5
San Francisco 5
San Giovanni in Persiceto 5
San Jose 5
Boston 4
Brooklyn 4
Chennai 4
Haiphong 4
Jundiaí 4
Kunming 4
Ningbo 4
Phoenix 4
Quận Một 4
Totale 5.265
Salva come PNG Salva come JPEG
Nome #
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 257
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 238
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 236
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 196
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 195
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 195
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 193
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 190
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 188
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 188
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 182
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 181
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 176
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 174
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 174
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 162
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 158
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 158
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 154
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 153
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 153
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 148
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 147
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 145
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 141
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 139
Nuclear inositide signaling in myelodysplastic syndromes. 139
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 139
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 138
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 137
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 136
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 129
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 128
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 126
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 126
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 125
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 123
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 122
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 121
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 118
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 115
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 110
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 104
Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. 104
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. 104
null 103
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 102
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 102
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 100
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 97
Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients 94
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 94
null 72
null 71
PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES 63
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 56
IS PI-PLC 1 EXPRESSION A RELIABLE PREDICTOR OF RESPONSE IN LOW RISK MDS PATIENTS TREATED WITH LOW-DOSE AZACITIDINE? RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY 53
null 43
null 41
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 36
Totale 8.092
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.733
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.733
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021574 0 0 0 0 0 33 36 33 78 31 27 336
2021/20221.128 121 16 57 97 98 72 36 49 39 150 177 216
2022/20231.301 100 176 77 181 116 96 59 118 206 13 100 59
2023/2024411 21 58 33 36 51 71 14 15 26 55 13 18
2024/20251.120 47 145 86 76 283 77 78 38 11 56 23 200
2025/20261.198 182 218 194 120 338 146 0 0 0 0 0 0
Totale 8.092